KRIBB publishes a monthly English newsletter. If you wish to receive, please leave your email address
Advanced biomedicine, aimed at eliminating the root causes of diseases and providing personalized treatment through cell and gene therapy,and aging research, aimed at accelerating the development of anti-aging therapies by accurately calculating the biological age, are considered to becore biotechnologies that will save humanity and promising technologies that will shape the future.In line with this trend, a conference has been organized to provide a platform for academic exchanges in the fields of high-tech biomedicineand anti-aging to lay the groundwork for solving national challenges in the bio sector and leading the bio transformation.The Korea Research Institute of Bioscience and Biotechnology (KRIBB) announced its plans to hold the 2023 KRIBB Annual Conference onDecember 5. Under the slogan, "Advanced Biomedicine & Aging, Opening New Horizon of Future Biotechnology,"the conference will feature a keynote lecture by KAIST Vice President for Research Lee Sang-yup, who founded the field of systems metabolic engineering,followed by a broad range of discussions among experts on advanced biomedicine and anti-aging research.A variety of other programs will also be organized for KRIBB to share the major research achievementsfrom the year 2023 and enable practical exchanges among the attendees.In his opening remarks, Kim Jang-sung, President of KRIBB, said, “As biotech emerges as a game changer in the global technology landscape,competition among nations to secure advanced biotechnologies is intensifying, and amid these circumstances,the Korea Research Institute of Bioscience and Biotechnology will endeavor to secure super gap technologiesby undertaking challenging and innovative R&D to serve as a leader in tackling national challenges and spearhead the bio transformation.”
The Korea Research Institute of Bioscience and Biotechnologyis endeavoring to strengthen international researchcollaborations in the field of biopharmaceuticals, including cell and gene therapy and bio big data, which have been designated as national strategic technologiesOn November 20 (Monday), KRIBB announced that it had signed an MOU withthe Milner Therapeutics Institute (MTI) of the University of Cambridge in the United Kingdom for research cooperation in the field of biopharmaceuticalsandheld a joint academic conference to identify areas of strengths of each party as well as common interests.Since its establishment in 2015, MTI has become one of the top biopharmaceutical research institutes in Europe in a short period of time andgained unrivaled capacity in developing new drugs based on artificial intelligence technology.The Milner Affiliate Program, which has helped drive the MTI‘s growth, includes 59 companies, 15 research institutions, and six venture capital firms from aroundthe world, and it brings together and maximizes the capabilities of industry, academia, research institutes, and hospitals in drug development such as jointresearch, clinical trials, and commercialization.With the signing of this MOU and registration in the Milner Affiliate Program, KRIBB has taken one step closer to achieving cutting-edge biotech innovation.The institute revealed its plans to undertake joint research with the MTI on promising technologies of the future such as cell and gene therapy, artificialorgans, and bio big data first before gradually expanding cooperation in other fields.“By working together with the Milner Therapeutics Institute, which plays a pivotal role in the strategic alliances established with global pharmaceutical companies,bioventures, and major hospitals, we will expand open innovation in the field of cutting-edge biotech and help strengthen Korea’s R&D capabilities in thebiopharmaceutical field,” said Kim Jang-sung, President of KRIBB.
